CellmAbs

CellmAbs is a Portuguese biotech spin-off focused on antibodies targeting cancer-specific antigens.

ShareLink copied

The record

Vertical
Oncology
Sub-segment
Antibody technologies
Product type
Therapeutics
Stage
Seed
Headquarters
Portugal
Region
Europe
Founded
2019
June 2019 seed investment
US$1.6 million
. Source

What they do

Founded in 2019 as a spin-off from NOVA University of Lisbon, CellmAbs was co-founded by CEO Nuno Prego Ramos and Prof. Paula Videira. Its work covered monoclonal antibodies targeting cancer-specific antigens, including antibody-drug conjugates, bispecific T-cell engagers and cell therapies. CellmAbs raised a single US$1.6 million seed investment in June 2019. Portugal Ventures and Bionova Capital are listed separately as supporters. On 9 January 2024, CellmAbs announced a patent assignment and licence agreement under which BioNTech acquired one preclinical antibody candidate and additional ADC technology. Terms included upfront and near-term payments, possible milestone payments and tiered royalties.

Investors

  • Portugal Ventures
  • Bionova Capital

Sources

  1. Press release reprint
  2. Público reporting
  3. The HealthTech Signal: CellmAbs and BioNTech

Related companies

Is this your company? Feature it